Evidence map›Paper›PMID 30379590›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019

Proproliferative function of adaptor protein GRB10 in prostate carcinoma.

Mohammad Imran Khan, Ahmed Al Johani, Abid Hamid, Bushra Ateeq, Nishat Manzar, Vaqar Mustafa Adhami, Rahul K Lall, Suvasmita Rath, Mario Sechi, Imtiaz Ahmad Siddiqui and 6 more

Erratum issuedAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Mohammad Imran KhanDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Ahmed Al JohaniDepartment of Biochemistry, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Abid HamidDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Bushra AteeqDepartment of Biological Sciences and Bioengineering, Molecular Oncology Laboratory, Indian Institute of Technology-Kanpur (IIT-K), Kanpur, India.
Nishat ManzarDepartment of Biological Sciences and Bioengineering, Molecular Oncology Laboratory, Indian Institute of Technology-Kanpur (IIT-K), Kanpur, India.
Vaqar Mustafa AdhamiDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Rahul K LallDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Suvasmita RathDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Mario SechiDepartment of Chemistry and Pharmacy, University of Sassari, Sassari, Italy.
Imtiaz Ahmad SiddiquiDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Hani ChoudhryDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Mazin A ZamzamiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Thomas C HavighurstDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Wei HuangDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
James M NtambiDepartment of Biochemistry, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Hasan MukhtarDepartment of Dermatology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
University of Wisconsin–Madison · USIndian Institute of Technology Kanpur · INKing Abdulaziz University · SAUniversity of Sassari · IT

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Developing Fisetin for the Managment of Prostate CancerR01CA160867 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA160867
6 · The paper itself

Abstract

Growth factor receptor-binding protein 10 (GRB10) is a well-known adaptor protein and a recently identified substrate of the mammalian target of rapamycin (mTOR). Depletion of GRB10 increases insulin sensitivity and overexpression suppresses PI3K/Akt signaling. Because the major reason for the limited efficacy of PI3K/Akt-targeted therapies in prostate cancer (PCa) is loss of mTOR-regulated feedback suppression, it is therefore important to assess the functional importance and regulation of GRB10 under these conditions. On the basis of these background observations, we explored the status and functional impact of GRB10 in PCa and found maximum expression in phosphatase and tensin homolog (PTEN)-deficient PCa. In human PCa samples, GRB10 inversely correlated with PTEN and positively correlated with pAKT levels. Knockdown of GRB10 in nontumorigenic PTEN null mouse embryonic fibroblasts and tumorigenic PCa cell lines reduced Akt phosphorylation and selectively activated a panel of receptor tyrosine kinases. Similarly, overexpression of GRB10 in PTEN wild-type PCa cell lines accelerated tumorigenesis and induced Akt phosphorylation. In PTEN wild-type PCa, GRB10 overexpression promoted mediated PTEN interaction and degradation. PI3K (but not mTOR) inhibitors reduced GRB10 expression, suggesting primarily PI3K-driven regulation of GRB10. In summary, our results suggest that GRB10 acts as a major downstream effector of PI3K and has tumor-promoting effects in prostate cancer.-Khan, M. I., Al Johani, A., Hamid, A., Ateeq, B., Manzar, N., Adhami, V. M., Lall, R. K., Rath, S., Sechi, M., Siddiqui, I. A., Choudhry, H., Zamzami, M. A., Havighurst, T. C., Huang, W., Ntambi, J. M., Mukhtar, H. Proproliferatve function of adaptor protein GRB10 in prostate carcinoma.

Indexed as

AnimalsCarcinogensCell Line, TumorCell ProliferationFibroblastsGene Knockdown TechniquesGRB10 Adaptor ProteinHumansMaleMechanistic Target of Rapamycin Complex 1MiceModels, BiologicalPhosphatidylinositol 3-KinasesProstatic NeoplasmsPTEN PhosphohydrolaseRNA, MessengerCarcinogensGRB10 Adaptor ProteinGRB10 protein, humanGrb10 protein, mouseMechanistic Target of Rapamycin Complex 1Phosphatidylinositol 3-KinasesPTEN PhosphohydrolasePTEN protein, humanPten protein, mouseRNA, MessengerGRB10mTORPI3KPTENRTKs

Identifiers

PMID30379590
PMCPMC6404554
OpenAlexW2899010172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.